KalVista’s Ekterly approved in EU and Switzerland

22 September 2025

Anglo-American pharma company KalVista Pharmaceuticals (Nasdaq: KALV) has won approval from both the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, for Ekterly (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

Ekterly is the first and only oral on-demand treatment for HAE in the European Union (EU) and Switzerland.

Henrik Balle Boysen, president of HAE International, said: “As the first orally administered on-demand therapy for HAE attacks, Ekterly provides patients and physicians with an important and welcome new HAE treatment option.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK